LEO Pharma Submits Anzupgo® Label Expansion for Adolescents with Chronic Hand Eczema
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 15 2025
0mins
Source: Businesswire
- Label Expansion Application: LEO Pharma has submitted a label expansion application to the EMA for Anzupgo® (delgocitinib) cream, aiming to provide treatment for adolescents aged 12 to 17 with moderate to severe chronic hand eczema, addressing a significant unmet need in this demographic.
- Clinical Trial Support: The application is backed by results from the DELTA TEEN trial, which demonstrated significant efficacy and safety of Anzupgo® in adolescent patients, potentially improving their quality of life significantly.
- Substantial Market Potential: Chronic hand eczema has a global prevalence rate of approximately 4.7%, with about 70% of severe patients reporting daily activity disruptions, indicating a strong demand for Anzupgo® among affected individuals.
- Strategic Commitment: This application underscores LEO Pharma's commitment to enhancing the quality of life for patients with skin diseases, which is expected to further solidify its leadership position in the medical dermatology sector.
Analyst Views on LEO
About LEO
BNY Mellon Strategic Municipals, Inc. (the Fund) is a diversified closed-end management investment company. The Fund’s investment objective is to maximize income exempt from federal income tax to the extent consistent with the preservation of capital. BNY Mellon Investment Adviser, Inc. (the Adviser) serves as the fund’s investment adviser. Under normal market conditions, the fund invests at least 80% of its net assets in municipal obligations. Generally, the fund invests at least 50% of its net assets in municipal bonds considered investment grade or the unrated equivalent as determined by BNY Mellon Investment Adviser, Inc. in the case of bonds, and in the two categories or the unrated equivalent as determined by the Adviser in the case of short-term obligations having or deemed to have maturities of less than one year. BNY Mellon Investment Adviser, Inc. serves as investment adviser of the Fund.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
